An Open-label Multicenter, Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of JYP0035 Capsule Monotherapy in Patients With Advanced Solid Tumors
Latest Information Update: 22 Nov 2024
At a glance
- Drugs JYP 0035 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Guangzhou JOYO Pharma
Most Recent Events
- 18 Nov 2024 Planned End Date changed from 15 Dec 2025 to 1 Dec 2027.
- 18 Nov 2024 Planned primary completion date changed from 15 Dec 2024 to 1 Dec 2026.
- 18 Nov 2024 Status changed from not yet recruiting to recruiting.